CMXHF Stock Chart & Stats
$124.63
-$1.97(-2.41%)
At close: 4:00 PM EDT
$124.63
-$1.97(-2.41%)
Day’s Range― - ―
52-Week Range$63.84 - $149.26
Previous CloseN/A
Volume151.00
Average Volume (3M)121.00
Market Cap
$58.31B
Enterprise Value$70.67B
Total Cash (Recent Filing)$1.51B
Total Debt (Recent Filing)$10.89B
Price to Earnings (P/E)―
Beta0.18
Next Earnings
Feb 09, 2027EPS Estimate
4.01Next Dividend Ex-DateN/A
Dividend Yield2.3%
Share Statistics
EPS (TTM)-5.29
Shares Outstanding479,884,280
10 Day Avg. Volume99
30 Day Avg. Volume121
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)3.74
Price to Sales (P/S)3.45
P/FCF Ratio18.88
Enterprise Value/Market Cap1.21
Enterprise Value/Revenue4.49
Enterprise Value/Gross Profit9.40
Enterprise Value/Ebitda13.95
Forecast
1Y Price Target
$123.85Price Target Upside-0.62% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering11
EPS Forecast (FY)4.27
Revenue Forecast (FY)$10.90B
Bulls Say, Bears Say
Bulls Say
Strong Cash GenerationPositive operating cash flow through a reported loss demonstrates that CSL’s products continue to generate cash and support financial commitments. This provides capacity to fund capital investment, maintain dividends, execute the buyback, and absorb ongoing portfolio remediation costs.
Transformation SavingsThe transformation program is already delivering savings ahead of target, while further reductions are planned over the next two fiscal years. These efficiencies can help protect margins, offset cost pressure, and provide funding for reinvestment in commercial and research initiatives.
Behring And Product MomentumImproving immunoglobulin momentum and growth from newer specialty products strengthen CSL’s core Behring franchise. Broader adoption across multiple therapies can diversify growth, improve product mix, and support more durable revenue expansion than reliance on a single launch.
Bears Say
Large Impairments And Statutory LossThe scale of impairments and the statutory loss indicate that prior portfolio assumptions have been materially reset. This weakens earnings quality, reduces equity support, and may constrain management’s flexibility while restructuring and remediation efforts work through the business.
Vifor Structural DeclineVifor faces several persistent pressures rather than a temporary sales setback, including generic competition, the ending of Velphoro’s TDAPA benefit, and TAVNEOS authorization loss. The expected decline creates a substantial drag on group growth and portfolio earnings over the medium term.
Albumin Pressure In ChinaSustained cost-containment and lower market value for albumin in China can pressure both revenue and product economics. Management continues to note market-value pressure despite stabilizing volumes, making recovery dependent on pricing and reimbursement conditions rather than demand alone.
CSL News
CMXHF FAQ
What was CSL’s price range in the past 12 months?
CSL lowest stock price was $63.84 and its highest was $149.26 in the past 12 months.
What is CSL’s market cap?
CSL’s market cap is $58.31B.
When is CSL’s upcoming earnings report date?
CSL’s upcoming earnings report date is Feb 09, 2027 which is in 127 days.
How were CSL’s earnings last quarter?
CSL released its earnings results on Aug 17, 2026. The company reported $2.26 earnings per share for the quarter, missing the consensus estimate of $2.355 by -$0.095.
Is CSL overvalued?
According to Wall Street analysts CSL’s price is currently Overvalued.
Does CSL pay dividends?
CSL pays a Semiannually dividend of $1.62 which represents an annual dividend yield of 2.3%. See more information on CSL dividends here
What is CSL’s EPS estimate?
CSL’s EPS estimate is 4.01.
How many shares outstanding does CSL have?
CSL has 479,884,280 shares outstanding.
What happened to CSL’s price movement after its last earnings report?
CSL reported an EPS of $2.26 in its last earnings report, missing expectations of $2.355. Following the earnings report the stock price went up 15.502%.
Which hedge fund is a major shareholder of CSL?
Currently, no hedge funds are holding shares in CMXHF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
CSL Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$123.85 (-0.62% Downside)
$123.85 (-0.62% Downside)
Blogger Sentiment
Bullish
CMXHF Sentiment 81%
Sector Average 65%
Sector Average 65%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-4.49%
12-Months-Change
Fundamentals
Return on Equity
2.30%
Trailing 12-Months
Asset Growth
-14.61%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
CSL
CSL Limited operates as a global biopharmaceutical company, engaged in the research, development, manufacturing, marketing, and distribution of diverse pharmaceutical and allied products. Its extensive international footprint includes key markets such as Australia, the United States, Germany, the United Kingdom, Switzerland, and China. The company is structured into two principal operating segments: CSL Behring and CSL Seqirus. CSL Behring focuses on plasma-derived therapies, encompassing both plasma products and recombinant treatments. This segment also conducts significant research into both plasma and non-plasma therapeutics and derives revenue from intellectual property licensing and royalties. In contrast, CSL Seqirus is dedicated to the manufacturing and worldwide distribution of non-plasma biotherapeutic products, alongside developing a range of influenza-related solutions. Founded in 1916, CSL Limited maintains its corporate headquarters in Parkville, Australia.
CMXHF Company Deck
CMXHF Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Negative
The call presented a mix of stabilization and operational progress (strong cash flow, ahead-of-plan transformation savings, Ig momentum in H2, successful new product launches and Seqirus share gains) but was overshadowed by very large impairments, a statutory net loss, and significant, structural headwinds in Vifor (anticipated ~25% revenue decline) plus continued pressure on albumin. While management has a clear remediation plan and delivered early positive operational signs, the scale and persistence of the portfolio and impairment issues materially weaken near-term financial prospects.View all CMXHF earnings summariesCMXHF Stock 12 Month Forecast
Average Price Target
$123.85
▼(-0.62% Downside)
Technical Analysis
―
Mesoblast Limited
―
Starpharma Holdings Limited
―
Telix Pharmaceuticals
―
Clarity Pharmaceuticals Ltd.
―
Ownership Overview
0.06% Insiders
5.09% Mutual Funds
<0.01% Other Institutional Investors
85.38% Public Companies and
Individual Investors